Overview Ruxolitinib in Operable Head and Neck Cancer Status: Recruiting Trial end date: 2022-06-30 Target enrollment: Participant gender: Summary The purpose of this study is to assess the safety and efficacy of ruxolitinib in patients with operable Head and neck squamous cell carcinoma (HNSCC) who are planned for definitive surgery. Phase: Phase 2 Details Lead Sponsor: University of California, San FranciscoCollaborators: Incyte CorporationIncyte Pharmaceuticals